SBFM Sunshine Biopharma, Inc.
Healthcare$0.42-13.46%ClosedMarket Cap: $2.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.11
P/S
0.07
EV/EBITDA
0.66
DCF Value
$-663.04
FCF Yield
-228.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
32.5%
Operating Margin
-12.9%
Net Margin
-17.0%
ROE
-25.6%
ROA
-21.6%
ROIC
-20.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $8.1M | 26.0% | $-1.4M | $-1.2M | $— | — |
| Q4 null | $8.6M | 34.2% | $-1.7M | $-2.1M | $— | — |
| FY null | $36.3M | 32.8% | $-4.5M | $-6.0M | $— | — |
| Q3 null | $9.4M | 32.6% | $-532.0K | $-883.8K | $— | — |
| Q2 null | $9.4M | 36.4% | $-992.8K | $-1.8M | $— | — |
| Q1 null | $8.9M | 30.7% | $-1.3M | $-1.2M | $— | — |
| Q4 null | $9.6M | 32.2% | $-2.0M | $-2.2M | $— | — |
| FY null | $34.9M | 30.6% | $-5.8M | $-5.1M | $— | — |
| Q3 null | $8.4M | 34.0% | $-1.1M | $-1.2M | $— | — |
| Q2 null | $9.3M | 25.3% | $-1.3M | $-494.3K | $— | — |
| Q1 null | $7.5M | 31.2% | $-1.4M | $-1.3M | $— | — |
| Q4 2023 | $7.7M | 33.4% | $-1.2M | $-1.3M | $-104.69 | — |